Whitehawk Therapeutics Presents New ADC Data at AACR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy WHWK?
Whitehawk Therapeutics announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research, AACR, Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA. "Across our three ADC programs, we have a consistent preclinical profile characterized by potent tumor regressions, high plasma stability and favorable tolerability in non-human primates, coupled with low systemic levels of free payload," said David Dornan, PhD, Chief Scientific Officer of Whitehawk Therapeutics. "These data support the potential for our next-generation bioconjugation and proprietary Carbon Bridge Cysteine Re-pairing linker-payload to deliver a differentiated, potentially best-in-class therapeutic index among TOP1i-based ADCs, which is fundamental to realizing the promise of ADCs for patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WHWK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WHWK
Wall Street analysts forecast WHWK stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.920
Low
7.00
Averages
7.00
High
7.00
Current: 3.920
Low
7.00
Averages
7.00
High
7.00
About WHWK
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Whitehawk Therapeutics Secures $87.5M PIPE Financing
- Financing Agreement: Whitehawk Therapeutics announced an $87.5 million PIPE financing agreement with existing investors, expected to close on May 14, 2026, with proceeds aimed at working capital and general corporate purposes.
- Share Sale Details: The company will sell 4.33 million shares of common stock at $3.92 per share and issue 17.99 million pre-funded warrants with an exercise price of $0.0001, reflecting confidence in future growth.
- Use of Proceeds: The financing proceeds, combined with existing cash and marketable securities, are expected to extend the company's cash runway into the second half of 2028, supporting its ADC pipeline and related development activities.
- Underwriter Lineup: Jefferies and Leerink Partners are acting as lead underwriters for the PIPE financing, with Oppenheimer & Co., Citizens Capital Markets, and Jones also involved, indicating strong market support for Whitehawk.
See More
Whitehawk Therapeutics Reports Progress on ADC Programs
- Preclinical Data Presentation: Whitehawk showcased preclinical data for HWK-007, HWK-016, and HWK-206 at AACR 2026, demonstrating tumor regressions at low doses, indicating the potential of their ADC therapies to provide more effective cancer treatment options for patients.
- Good Tolerability: Both HWK-007 and HWK-016 exhibited favorable tolerability in non-human primates, with a highest non-severe dose (HNSTD) of 60 mg/kg and low systemic levels of free payload below 0.01% AUC, highlighting their safety and efficacy.
- Clinical Trial Progress: Phase 1 trials for HWK-007 and HWK-016 are ongoing, while HWK-206 is on track for IND submission in mid-2026 and initiation of Phase 1 trials in Q3 2026, marking continued advancement in the company's drug development efforts.
- Platform Advantage: Whitehawk's Carbon Bridge Cysteine Re-pairing platform provides a differentiated therapeutic index for ADCs, potentially allowing the company to stand out in a competitive market, thereby enhancing its position in the oncology treatment landscape.
See More
Whitehawk Presents Preclinical Data for Next-Gen ADCs at AACR 2026
- Significant Tumor Regression: Preclinical data for HWK-007, HWK-016, and HWK-206 show tumor regressions at low single-digit mg/kg doses across various cancer models, with favorable tolerability (HNSTD at 60 mg/kg), establishing a strong foundation for future clinical applications.
- Clinical Trial Progress: Ongoing Phase 1 trials for HWK-007 and HWK-016, with an IND submission for HWK-206 expected in mid-2026 and initiation of the Phase 1 trial in Q3 2026, indicating robust advancement in the company's drug development pipeline.
- Unique Bioconjugation Technology: Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform offers a differentiated therapeutic index, potentially achieving best-in-class efficacy among TOP1i-based ADCs, thereby enhancing the company's competitive edge in oncology treatments.
- High Stability and Low Toxicity: All three ADCs demonstrate favorable pharmacokinetics with low systemic levels of free payload (≤0.01% AUC) in non-human primates, underscoring their safety and effectiveness for clinical use.
See More
Whitehawk Therapeutics Presents New ADC Data at AACR 2026
- Preclinical Data Presentation: Whitehawk showcased preclinical data for HWK-007, HWK-016, and HWK-206 at AACR 2026, demonstrating tumor regressions at low doses, indicating the potential of their ADC therapies to provide more effective treatment options for cancer patients.
- Outstanding Performance of HWK-007: HWK-007 achieved tumor regressions at doses as low as 1 mg/kg in small cell lung cancer and ovarian cancer models, and exhibited favorable tolerability in non-human primates with an HNSTD of 60 mg/kg, highlighting its safety and efficacy for clinical applications.
- Innovation with HWK-016: HWK-016 selectively binds to membrane-bound MUC16, avoiding interactions with circulating CA125, and demonstrated the ability to achieve tumor regressions at a dose of 1 mg/kg in ovarian cancer models, enhancing its competitive edge in the ADC market.
- Future Plans for HWK-206: HWK-206 is set to submit an IND application in mid-2026 and initiate a Phase 1 clinical trial in Q3 2026, achieving tumor regressions at doses as low as 2 mg/kg in small cell lung cancer models, showcasing favorable pharmacokinetics and tolerability.
See More
Whitehawk Therapeutics Shares Surge on Coverage Launch
- Market Rating Launch: Citizens initiated coverage of Whitehawk Therapeutics (WHWK) with a Market Outperform rating, and analyst Reni Benjamin's bullish outlook has driven the stock price surge, reflecting market confidence in the company's future potential.
- Clinical Data Release: Whitehawk plans to present three preclinical abstracts at next week's American Association for Cancer Research annual meeting, covering its next-gen antibody-drug conjugate (ADC) candidates HWK-016, HWK-007, and HWK-206, which are expected to attract investor interest.
- Cash Position Advantage: With a cash position of $145.7 million, Whitehawk is well-positioned to support its future R&D and market expansion, further bolstering investor confidence in its operations.
- Target Price Setting: The analyst has set an $8 target price for Whitehawk's stock based on a comparable market capitalization analysis and discounted M&A/licensing deal analysis in the ADC space, indicating strong mid-to-long-term potential.
See More
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Target Advantage: MUC16 is expressed at least two-fold higher in ovarian cancer compared to other emerging targets and is stably expressed in the most aggressive and common subtypes of endometrial cancer, indicating its potential as a clinically meaningful ADC target that could provide new treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing a Phase 1 clinical trial for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, which will provide critical clinical evidence for its application in cancer treatment.
- Technological Innovation: HWK-016 utilizes a stable, cleavable linker to selectively target the membrane-bound, non-shed portion of MUC16, overcoming limitations faced by earlier MUC16-targeted ADCs in tumor delivery, potentially enhancing therapeutic efficacy and improving patient survival rates.
- Biological Rationale: Real-world data presented at the SGO meeting further reinforce MUC16 as a 'super expressed' target for gynecological cancers, indicating that the development of HWK-016 aligns with current cancer treatment needs and may improve patient outcomes.
See More
Whitehawk Therapeutics Secures $87.5M PIPE Financing
- Financing Agreement: Whitehawk Therapeutics announced an $87.5 million PIPE financing agreement with existing investors, expected to close on May 14, 2026, with proceeds aimed at working capital and general corporate purposes.
- Share Sale Details: The company will sell 4.33 million shares of common stock at $3.92 per share and issue 17.99 million pre-funded warrants with an exercise price of $0.0001, reflecting confidence in future growth.
- Use of Proceeds: The financing proceeds, combined with existing cash and marketable securities, are expected to extend the company's cash runway into the second half of 2028, supporting its ADC pipeline and related development activities.
- Underwriter Lineup: Jefferies and Leerink Partners are acting as lead underwriters for the PIPE financing, with Oppenheimer & Co., Citizens Capital Markets, and Jones also involved, indicating strong market support for Whitehawk.
See More
Whitehawk Therapeutics Reports Progress on ADC Programs
- Preclinical Data Presentation: Whitehawk showcased preclinical data for HWK-007, HWK-016, and HWK-206 at AACR 2026, demonstrating tumor regressions at low doses, indicating the potential of their ADC therapies to provide more effective cancer treatment options for patients.
- Good Tolerability: Both HWK-007 and HWK-016 exhibited favorable tolerability in non-human primates, with a highest non-severe dose (HNSTD) of 60 mg/kg and low systemic levels of free payload below 0.01% AUC, highlighting their safety and efficacy.
- Clinical Trial Progress: Phase 1 trials for HWK-007 and HWK-016 are ongoing, while HWK-206 is on track for IND submission in mid-2026 and initiation of Phase 1 trials in Q3 2026, marking continued advancement in the company's drug development efforts.
- Platform Advantage: Whitehawk's Carbon Bridge Cysteine Re-pairing platform provides a differentiated therapeutic index for ADCs, potentially allowing the company to stand out in a competitive market, thereby enhancing its position in the oncology treatment landscape.
See More
Whitehawk Presents Preclinical Data for Next-Gen ADCs at AACR 2026
- Significant Tumor Regression: Preclinical data for HWK-007, HWK-016, and HWK-206 show tumor regressions at low single-digit mg/kg doses across various cancer models, with favorable tolerability (HNSTD at 60 mg/kg), establishing a strong foundation for future clinical applications.
- Clinical Trial Progress: Ongoing Phase 1 trials for HWK-007 and HWK-016, with an IND submission for HWK-206 expected in mid-2026 and initiation of the Phase 1 trial in Q3 2026, indicating robust advancement in the company's drug development pipeline.
- Unique Bioconjugation Technology: Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform offers a differentiated therapeutic index, potentially achieving best-in-class efficacy among TOP1i-based ADCs, thereby enhancing the company's competitive edge in oncology treatments.
- High Stability and Low Toxicity: All three ADCs demonstrate favorable pharmacokinetics with low systemic levels of free payload (≤0.01% AUC) in non-human primates, underscoring their safety and effectiveness for clinical use.
See More
Whitehawk Therapeutics Presents New ADC Data at AACR 2026
- Preclinical Data Presentation: Whitehawk showcased preclinical data for HWK-007, HWK-016, and HWK-206 at AACR 2026, demonstrating tumor regressions at low doses, indicating the potential of their ADC therapies to provide more effective treatment options for cancer patients.
- Outstanding Performance of HWK-007: HWK-007 achieved tumor regressions at doses as low as 1 mg/kg in small cell lung cancer and ovarian cancer models, and exhibited favorable tolerability in non-human primates with an HNSTD of 60 mg/kg, highlighting its safety and efficacy for clinical applications.
- Innovation with HWK-016: HWK-016 selectively binds to membrane-bound MUC16, avoiding interactions with circulating CA125, and demonstrated the ability to achieve tumor regressions at a dose of 1 mg/kg in ovarian cancer models, enhancing its competitive edge in the ADC market.
- Future Plans for HWK-206: HWK-206 is set to submit an IND application in mid-2026 and initiate a Phase 1 clinical trial in Q3 2026, achieving tumor regressions at doses as low as 2 mg/kg in small cell lung cancer models, showcasing favorable pharmacokinetics and tolerability.
See More
Whitehawk Therapeutics Shares Surge on Coverage Launch
- Market Rating Launch: Citizens initiated coverage of Whitehawk Therapeutics (WHWK) with a Market Outperform rating, and analyst Reni Benjamin's bullish outlook has driven the stock price surge, reflecting market confidence in the company's future potential.
- Clinical Data Release: Whitehawk plans to present three preclinical abstracts at next week's American Association for Cancer Research annual meeting, covering its next-gen antibody-drug conjugate (ADC) candidates HWK-016, HWK-007, and HWK-206, which are expected to attract investor interest.
- Cash Position Advantage: With a cash position of $145.7 million, Whitehawk is well-positioned to support its future R&D and market expansion, further bolstering investor confidence in its operations.
- Target Price Setting: The analyst has set an $8 target price for Whitehawk's stock based on a comparable market capitalization analysis and discounted M&A/licensing deal analysis in the ADC space, indicating strong mid-to-long-term potential.
See More
Whitehawk Therapeutics Advances MUC16-Targeted ADC Development
- MUC16 Target Advantage: MUC16 is expressed at least two-fold higher in ovarian cancer compared to other emerging targets and is stably expressed in the most aggressive and common subtypes of endometrial cancer, indicating its potential as a clinically meaningful ADC target that could provide new treatment options for patients.
- Clinical Trial Progress: Whitehawk's HWK-016 is currently undergoing a Phase 1 clinical trial for advanced ovarian and endometrial cancers, with initial data expected in the first half of 2027, which will provide critical clinical evidence for its application in cancer treatment.
- Technological Innovation: HWK-016 utilizes a stable, cleavable linker to selectively target the membrane-bound, non-shed portion of MUC16, overcoming limitations faced by earlier MUC16-targeted ADCs in tumor delivery, potentially enhancing therapeutic efficacy and improving patient survival rates.
- Biological Rationale: Real-world data presented at the SGO meeting further reinforce MUC16 as a 'super expressed' target for gynecological cancers, indicating that the development of HWK-016 aligns with current cancer treatment needs and may improve patient outcomes.
See More
